Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 130 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Young Tulsa Mom Grows Closer To Her Own Mom During Almost... May 10, 2019 Facing Crisis After Crisis During Cancer: How to Cope April 28, 2022 Breaking down changes in NHS cancer waiting times in England August 17, 2023 ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 Load more HOT NEWS FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities First targeted treatment approved for advanced prostate cancer on NHS in... The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment...
